Before you come in…
You should be 19+ (or the legal age in your province) to hang out in the Weedverse. Quick, painless, very Canadian.
Education and journalism, not sales. We don’t sell cannabis.
The Science Is Real
Cannabis education that doesn't require a PhD to read or a marketing degree to decode. Two layers. One for the consumer. One for the nerd. No judgment either way. Every topic below gives you the essentials up front, then opens a door into the full research for the people who want to go deeper.
THC is the compound that gets you high. It is responsible for the euphoria, the altered sense of time, the appetite boost, and — at higher doses — the anxiety. Delta-9-tetrahydrocannabinol is the most studied cannabinoid in the plant, and the one most consumers fixate on when reading a label. The number on the package is not the whole story, but it is where the conversation starts.
THC binds to CB1 receptors in the brain — the receptors that regulate mood, memory, pain perception, appetite, and motor coordination. That binding is what produces the psychoactive effect. But dose matters more than most people realize. Low doses of THC can ease anxiety and improve mood. Higher doses can flip the switch in the other direction and cause the exact anxiety it was supposed to relieve. The difference between therapeutic and overwhelming is often a matter of milligrams, not willpower.
The medical track record is real. Dronabinol (synthetic THC) is FDA-approved for chemotherapy-induced nausea. Nabilone, another synthetic cannabinoid, carries the same approval. These are not folk remedies — they are pharmaceutical products that went through clinical trials because the compound works. The question was never whether THC does something. The question is what it does at specific doses, in specific people, through specific delivery methods.
What to watch for: short-term memory impairment and motor coordination effects while THC is active. These are temporary in adult use. The more serious concern involves chronic heavy use during adolescence, where research has associated it with persistent cognitive effects that may not fully reverse. The developing brain and the mature brain are not the same audience.
Go Deeper: THC Deep Dive →CBD does not get you high. It is the second most abundant cannabinoid in the cannabis plant, and it arrived in the public consciousness as a cure for everything from anxiety to inflammation to that weird thing your knee does when it rains. The reality is more measured, more interesting, and significantly less marketable than the wellness industry would prefer.
Cannabidiol works through complex pharmacological pathways — dampening inflammation, modulating pain signals, and calming overactive neural circuits. It does not bind to CB1 receptors the way THC does. Instead, it influences the endocannabinoid system indirectly, which is part of why it does not produce intoxication and part of why its effects are subtler and harder to pin down in a marketing tagline.
The proven win is Epidiolex — a CBD-based pharmaceutical approved for severe childhood epilepsy syndromes (Dravet syndrome and Lennox-Gastaut syndrome). This is not anecdotal. This is rock-solid clinical trial data that led to FDA approval. The compound demonstrably reduces seizure frequency in patients who had exhausted other options. That is the gold standard of evidence, and CBD has it.
The gap: most wellness products on the market contain CBD doses far lower than those used in clinical trials. A 25mg gummy is not the same intervention as the doses studied in epilepsy research. That does not mean lower doses do nothing — it means the evidence base for what you are actually buying is thinner than the packaging implies.
What to watch for: CBD interacts with liver enzymes (specifically CYP3A4 and CYP2C19) that process many common medications, including blood thinners, certain heart medications, and some antidepressants. If you take prescription drugs, this is not a footnote — it is a conversation with your pharmacist.
Go Deeper: CBD Deep Dive →CBN is what THC turns into as it ages. Leave cannabis exposed to air and light long enough and the THC oxidizes into cannabinol. It is mildly psychoactive — roughly one-quarter to one-tenth of THC's potency, depending on the study — and the market has crowned it the "sleep cannabinoid" based on a combination of early research and consumer demand for a natural sleep aid that is not melatonin.
A 2024 clinical trial showed improvement in sleep quality at all dose levels tested compared to placebo. That is encouraging. But a separate study found that CBD isolate produced similar sleep improvements, which complicates the narrative that CBN is uniquely effective for sleep. Was it the CBN specifically? Was it the mild sedation from any cannabinoid interaction? The research is not mature enough to answer that definitively.
The evidence is early and promising, not settled. That is an honest position. The products on the shelf are ahead of the science, which is common in cannabis and not automatically a problem — but consumers should know the difference between "clinical proof" and "clinical interest." CBN sits in the second category. It may graduate to the first. We will update this page when it does.
Go Deeper: CBN Deep Dive →CBG starts the whole family tree. Cannabigerolic acid (CBGA) is the precursor molecule from which the plant synthesizes THCA, CBDA, and CBCA. Those acids then decarboxylate into THC, CBD, and CBC respectively. Without CBGA, none of the major cannabinoids exist. "Mother cannabinoid" is not a marketing term — it describes the chemistry.
CBG itself is non-intoxicating. It will not get you high. Preclinical research has flagged it as anti-inflammatory, antibacterial (potent against MRSA in laboratory studies), and potentially neuroprotective. The antibacterial findings in particular have attracted attention from researchers looking for new tools against antibiotic-resistant infections. That is a legitimate and serious line of inquiry.
The catch: almost all of this research is preclinical. Animal models and cell cultures, not human clinical trials. Preclinical results are the beginning of the scientific process, not the conclusion. Compounds that look promising in a petri dish fail in human trials routinely. CBG may prove to be everything the early research suggests. It may not. "Mother cannabinoid" describes its chemistry, not its therapeutic rank. The distinction matters.
Go Deeper: CBG Deep Dive →THCV is structurally similar to THC but with a shorter molecular tail, and that small difference gives it a completely different personality. At low doses, THCV blocks the CB1 receptor — the same receptor THC activates. At higher doses, it can flip and activate it. This dose-dependent switching between antagonist and agonist is unusual among cannabinoids and is part of why THCV has attracted research interest disproportionate to its natural abundance in the plant.
The appetite angle is the one that gets attention: THCV suppresses appetite. That is the pharmacological opposite of the munchies. It also appears to improve insulin sensitivity and may help with blood sugar regulation. Early human trials in type 2 diabetics showed reduced fasting blood glucose, which is a meaningful clinical endpoint. This is not a weight-loss supplement claim — this is metabolic research with measurable biomarkers.
The supply problem: THCV is naturally rare. Most cannabis strains contain it in trace amounts. The exception is certain African sativa landraces — Durban Poison being the most commonly cited example. Breeding programs and biosynthesis may eventually solve the supply issue, but for now, high-THCV products are uncommon and typically expensive. If a product claims significant THCV content, check the lab results.
Go Deeper: THCV Deep Dive →Your body produces its own cannabinoids. This is not a fringe theory or something invented at a dispensary. The endocannabinoid system (ECS) was discovered through cannabis research in the early 1990s, and it is one of the most important regulatory systems in human physiology. Most education about cannabis skips this part entirely, which is like teaching someone to drive without mentioning the engine.
The ECS runs on two main receptor types. CB1 receptors are concentrated in the brain and central nervous system — they regulate mood, memory, pain perception, appetite, and motor coordination. CB2 receptors are found primarily on immune cells and in the gut — they modulate inflammation and immune response. When you consume cannabis, the plant cannabinoids interact with these same receptors. That is why THC produces its effects and why CBD influences the system differently.
Your body produces two primary endocannabinoids to operate this system: anandamide and 2-AG. Anandamide — named from the Sanskrit word for "bliss" — was the first to be identified. 2-AG is approximately 1,000 times more abundant in the brain. Together, they maintain homeostasis: when something in your body drifts out of range, the ECS activates to bring it back. Sleep, appetite, pain, mood, immune function — the ECS touches all of it.
The runner's high that people attribute to endorphins? Current research suggests endocannabinoids — specifically anandamide — are the primary driver. Exercise boosts endocannabinoid levels. So do omega-3 fatty acids. Your body is already running this system. Cannabis interacts with it. Understanding the system is the foundation for understanding everything the plant does.
Go Deeper: Endocannabinoid System Deep Dive →The delivery method is not a lifestyle preference. It is pharmacokinetics. The same compound, consumed differently, produces different onset times, different durations, different intensity curves, and in some cases a literally different molecule reaching your brain. Understanding this is the difference between a controlled experience and a four-hour mistake.
Onset: 6 to 10 minutes. Duration: 2 to 3 hours. Inhalation delivers cannabinoids through the lungs into the bloodstream rapidly, which allows you to control the dose in close to real time. You feel it, you assess it, you decide whether to continue. That feedback loop is the primary advantage of inhalation as a delivery method.
The tradeoff: combustion produces byproducts. Smoking cannabis generates many of the same irritants as burning any organic material. Vaporizing at controlled temperatures reduces this significantly but does not eliminate it entirely. The harm reduction math is straightforward — lower temperatures, fewer combustion byproducts, less respiratory irritation.
Onset: 30 minutes to 2 hours. Duration: 4 to 8 hours. Edibles go through the digestive system and liver, where the body converts delta-9-THC into 11-hydroxy-THC. That is a different molecule. It may cross the blood-brain barrier more efficiently than delta-9, which is why edibles can produce a more intense and longer-lasting experience than the same amount of THC inhaled.
"Start low, go slow" is not a slogan. It is pharmacokinetics. The delayed onset means consumers who take a second dose because the first "isn't working" are doubling a dose that has not yet arrived. Five milligrams is a reasonable starting point for anyone without established tolerance. Patience is the active ingredient.
Onset: 15 to 60 minutes. Duration: 4 to 6 hours. Sublingual products — oils, tinctures, strips — are designed to absorb through the mucous membranes under the tongue, bypassing the digestive system for faster onset than edibles. In practice, a significant portion of the dose gets swallowed anyway, which means you often get a hybrid of sublingual and oral absorption. The experience timeline is less predictable than either pure inhalation or pure edible consumption.
Topical products — creams, balms, salves — deliver cannabinoids to local tissue. They do not cross into the bloodstream in meaningful amounts. They will not get you high. They are designed for localized relief: sore muscles, joint inflammation, skin conditions. That is the lane, and it is a legitimate one.
Transdermal products are different. Transdermal patches and gels are engineered to cross the skin barrier and enter systemic circulation. They can produce psychoactive effects. They deliver slow, steady doses over extended periods. The market frequently blurs the line between topical and transdermal, and consumers end up confused about whether the product they are buying will affect them systemically or locally. Read the label. If it says transdermal, it means systemic.
Concentrates strip away plant material and deliver cannabinoids and terpenes at potencies that dwarf dried flower. They are not inherently dangerous and they are not for beginners. They deserve a real explanation, because "it's just stronger weed" misses the point entirely. The extraction method, the source material, and the post-processing all determine what you are actually consuming.
Dry sift and kief: The simplest form. Trichomes are mechanically separated from flower using screens or tumblers. No chemicals, no heat, no complexity. The quality depends entirely on the starting material and the mesh size.
Ice water hash (bubble hash): Cannabis is agitated in ice water, which makes trichome heads brittle and snaps them from the plant. The mixture is filtered through progressively finer mesh bags. High-quality ice water hash — rated on a star system from 1 to 6 — is one of the most prized forms of concentrate in the market.
Rosin: Heat and pressure applied to flower or hash squeeze out cannabinoid-rich resin without any solvent. What goes in is what comes out. The simplicity is the appeal.
Live rosin: Rosin made from fresh-frozen cannabis rather than dried and cured flower. Freezing immediately after harvest preserves the volatile terpene profile that drying would diminish. Live rosin from high-quality ice water hash is currently the pinnacle of solventless extraction. The price reflects it.
BHO (butane hash oil): Butane is used to dissolve cannabinoids and terpenes from plant material. The solvent is then purged through heat and vacuum. Different purging techniques and post-processing produce different consistencies — shatter (glass-like), budder (creamy), crumble (dry, crumbly), sauce (terpene-rich liquid with crystalline structures), and diamonds (nearly pure THCA crystals). Same extraction, different finishing.
CO2 extraction: Supercritical carbon dioxide acts as the solvent. More expensive equipment, cleaner process, and the CO2 evaporates completely. Widely used for vape cartridges and commercial-scale production.
Ethanol extraction: Food-grade ethanol dissolves cannabinoids efficiently. Common in large-scale production for edibles, tinctures, and distillate. Less terpene preservation than BHO or CO2 methods.
Distillation further refines extract into an odourless, flavourless oil that is 85 to 95 percent pure cannabinoid. Most vape cartridges and many edibles use distillate as their base. Terpenes are stripped during the process and may be re-added afterward — either cannabis-derived or botanical (non-cannabis plant sources).
Full-spectrum products preserve the original cannabinoid and terpene profile of the source plant. Distillate is a blank slate that can be flavoured and dosed with precision. Neither is inherently superior. They serve different purposes. But the consumer should know which one they are buying, and the labelling does not always make it obvious.
The THC percentage on the label is not what you think it is. Most cannabis flower contains THCA (the acid form) which converts to THC when heated. The Total THC calculation is: THCA × 0.877 + THC. That 0.877 factor accounts for the molecular weight lost during decarboxylation. A product labelled at 25% THCA contains roughly 21.9% Total THC once you account for the conversion. The industry puts the big number on the front of the package. The math lives in the fine print.
More importantly: higher THC does not always mean a better experience. Terpene content is a stronger predictor of subjective quality than THC percentage. A terpene profile above 2% total terpenes is considered strong and usually indicates a well-grown, properly cured product. Below 1% is flat — the aromatics that shape the experience have either been lost to poor handling or were never there. The market's obsession with THC percentage has trained consumers to chase the wrong number.
Health Canada requires licensed producers to submit products for laboratory testing. Mandatory panels include cannabinoid potency, microbial contamination (mould, bacteria, yeast), heavy metals, pesticide residues, and residual solvents for extracted products. Labs operate within defined tolerance bands, which means minor variation between the label and the test result is expected and permitted. Significant deviation is a compliance issue.
Our testing standard goes beyond the regulatory minimum. We evaluate the full experience: does the label match what is in the bag? Does the terpene profile survive from cultivation to retail? Is the cure done properly? Is the moisture level appropriate? The lab certificate tells you what was in the sample the producer submitted. Our reviews tell you what was in the package you bought.
Go Deeper: Product Testing Deep Dive →Cannabis is used by a significant number of people for mental health management. Some of them have prescriptions. Many do not. Among those without prescriptions are neurodivergent individuals — people with ADHD, autism spectrum conditions, PTSD, anxiety disorders, chronic depression — who report that cannabis works better for them than conventional medications they have tried. That is their lived experience, and it is not our place to dismiss it.
The stigma of "the pothead" has done real damage to this conversation. The caricature of the lazy, unfocused cannabis consumer has been used for decades to dismiss legitimate self-medication, to justify discriminatory policies, and to prevent honest research into how and why cannabis affects mental health. That caricature is wrong. It was always wrong. The people using cannabis to manage their mental health are not the stereotype. They are your colleagues, your neighbours, your family members. They deserve better than ridicule, and they deserve better than blind cheerleading.
Because the risks are real. The relationship between cannabis and the schizophrenic spectrum of disorders is supported by consistent evidence. For individuals with a predisposition to psychotic disorders — whether diagnosed or latent — cannabis use, particularly high-THC cannabis used frequently during adolescence and young adulthood, can significantly worsen outcomes. It can accelerate the onset of psychotic episodes. It can increase their severity. The science on this point is not ambiguous. Honest cannabis education requires saying so clearly.
Cannabis does not cause schizophrenia in people without a predisposition. But it can activate and amplify a vulnerability that already exists. The challenge is that many people do not know whether they carry that predisposition until symptoms emerge. Family history is the strongest indicator. If psychotic disorders run in your family, the risk calculus around cannabis use — particularly high-dose, high-frequency use — shifts substantially.
Responsible use means knowing your own risk factors. It means being honest with yourself about why you are using, how much you are using, and whether the pattern is serving you or running you. It means recognizing that a substance which helps one person manage their anxiety can worsen another person's mental health condition. Individual biology is not a talking point — it is the variable that determines the outcome.
This is not a prescription. It is not a dismissal. It is the conversation the cannabis industry needs to have honestly and has mostly avoided because nuance does not sell product. The advocates who pretend there are no risks do as much harm as the prohibitionists who pretended there were no benefits. The truth lives in the middle, and that is where we intend to stay.
Everything on this page is built from public health and peer-reviewed sources. We cite, we link, and we update as the science moves.
• Health Canada — Cannabis health effects and risks
• National Institute on Drug Abuse (NIDA) — Cannabis (Marijuana) research
• Government of Canada — Cannabis Act (S.C. 2018, c. 16)
• U.S. FDA — Products containing cannabis or cannabis-derived compounds
Full per-topic citations live in the Deep Dives library.
From legally required crop to criminal record machine and back. 412 years, honestly told.
Canada's first European farmer grew cannabis. Colonists could be fined for NOT growing hemp — in some colonies it was legal tender. Then, in a late-night session in 1923, somebody added “Indian Hemp” to a bill by hand — nobody knows who — and Canada banned a plant most Canadians had never heard of, fourteen years before the Americans. What followed: half a million criminal records, a royal commission that recommended legalization in 1972 and was ignored for 46 years, and a road back that ran through one sick man and the Charter of Rights.
Every claim sourced. The racial history told straight. And yes — the word “canvas” really does come from “cannabis.”
Go Deeper: The Complete History →